Quick Answer
Wave Life Sciences Ltd. reported Diluted EPS of $1.21 per share (loss) for fiscal year 2025.
Wave Life Sciences Ltd. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.21 | -72.9% |
| 2024 | -$0.70 | -29.6% |
| 2023 | -$0.54 | +73.7% |
| 2022 | -$2.05 | +13.1% |
| 2021 | -$2.36 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.32 | +31.9% | -3.2% |
| June 30, 2025 | -$0.31 | -24.0% | -6.9% |
| March 31, 2025 | -$0.29 | -20.8% | +38.3% |
| September 30, 2024 | -$0.47 | -771.4% | -88.0% |
| June 30, 2024 | -$0.25 | -25.0% | -4.2% |
| March 31, 2024 | -$0.24 | +11.1% | -442.9% |
| September 30, 2023 | $0.07 | +116.7% | +135.0% |
| June 30, 2023 | -$0.20 | +67.7% | +25.9% |
- Wave Life Sciences Ltd. showed a decrease of -72.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Wave Life Sciences Ltd.’s diluted eps has grown by 48.7% (from $2.36 per share (loss) to $1.21 per share (loss)).
- The most recent figure is from Wave Life Sciences Ltd.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: